Minerva Neurosciences (NASDAQ:NERV) Announces Earnings Results

Minerva Neurosciences (NASDAQ:NERV) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.05) by $0.49, Zacks reports.

Minerva Neurosciences Stock Down 1.6 %

NERV stock opened at $1.79 on Tuesday. The stock’s 50 day moving average is $2.18 and its two-hundred day moving average is $2.40. Minerva Neurosciences has a 52-week low of $1.77 and a 52-week high of $7.53. The company has a market capitalization of $12.52 million, a PE ratio of -4.07 and a beta of 0.12.

Analyst Upgrades and Downgrades

NERV has been the subject of several analyst reports. StockNews.com started coverage on shares of Minerva Neurosciences in a research note on Saturday. They issued a “sell” rating for the company. HC Wainwright reissued a “neutral” rating and issued a $5.00 price objective on shares of Minerva Neurosciences in a research report on Wednesday, November 6th.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.